Keep up-to-date with PrECOG by visiting our news page regularly.
After phase 2 trials showed promising survival for the combination of durvalumab during and after standard chemotherapy, collaborators in the US, Australia, and New Zealand open the phase 3 DREAM3R trial For Immediate Release March 17, 2021 Contact Diane Dragaud Director of Communications (215) 789-3631 Inquire by email Philadelphia—The DREAM3R phase three clinical trial is […]
Second Interim Analysis of Adjuvant Study for HR+, HER2- Early Breast Cancer demonstrates that there is little chance of palbociclib reducing the risk of recurrence For Immediate Release May 29, 2020 Vienna, Brussels, Chicago, Philadelphia, Neu-Isenburg/Frankfurt, Pittsburgh—The Austrian Breast & Colorectal Cancer Study Group (ABCSG), […]
Phase 2 trial PrE0505 selected for oral presentation at ASCO 2020; data signals the combination should advance to a randomized phase 3 study For Immediate Release May 20, 2020 Contact Diane Dragaud Director of Communications (215) 789-3631 Inquire by email Philadelphia, PA—PrECOG, LLC is reporting clinical efficacy and biomarker analyses from its single-arm phase two […]
Study seeks to confirm predictive and prognostic biomarkers demonstrating pelareorep can expand application of checkpoint inhibitors in HR+-metastatic breast cancer SAN DIEGO, CA, CALGARY, AB, and PHILADELPHIA, PA, October 22, 2019 – Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, and PrECOG LLC, a leading cancer research network, […]
The results from the PrE0204 trial, A Multi-Institutional, Single Arm, Two-Stage Phase II Trial of Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients With Advanced or Metastatic Cholangiocarcinoma was published by Sahai V, Catalano P, Zalupski MM, et.al. The article appeared online before print in JAMA Oncology on Aug 30, 2018. [NCT02181634, doi: 10.1001/jamaoncol.2018.3277].